title: A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections.
abstract: Options for treatment of multidrug-resistant (MDR) Acinetobacter baumannii infections are extremely limited. Minocycline intravenous is active against many MDR strains of Acinetobacter, and Clinical and Laboratory Standards Institute breakpoints exist to guide interpretation of minocycline susceptibility results with Acinetobacter. In addition, minocycline intravenous holds a US Food and Drug Administration indication for treatment of infections caused by Acinetobacter. There is an accumulating amount of literature reporting successful use of minocycline intravenous for treatment of serious MDR Acinetobacter infections, particularly for nosocomial pneumonia. These results, coupled with the generally favorable tolerability of minocycline intravenous, support its use as a viable therapeutic option for treatment of MDR Acinetobacter infections.
authors.affiliation: Department of Pharmacy, Barnes-Jewish Hospital Pharmacy Practice Department, St Louis College of Pharmacy.
authors.forename: David J
authors.initials: DJ
authors.lastname: Ritchie
authors.affiliation: Pharmacy Practice Department, St Louis College of Pharmacy Infectious Diseases Clinic, Washington University School of Medicine, St Louis, Missouri.
authors.forename: Alexandria
authors.initials: A
authors.lastname: Garavaglia-Wilson
mesh_terms: D000150:Acinetobacter / Q000187:drug effects*; D000151:Acinetobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D061605:Administration, Intravenous; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D008911:Minocycline / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000900:Anti-Bacterial Agents; D008911:Minocycline
keywords: Acinetobacter; intravenous; minocycline; multidrug-resistant